A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.

Lijun Liang,Lei Wang,Panrong Zhu,Youyou Xia,Yun Qiao,Jiang Wu, Wei Zhuang, Jiayan Fei,Yixuan Wen,Xiaodong Jiang

Clinical Colorectal Cancer（2018）

引用 33|浏览2

暂无评分

摘要

Our results suggested that apatinib was active as a third-line treatment of refractory mCRC with a manageable tolerability profile. In addition, preliminary data suggested that the efficacy of apatinib would not be affected by previous bevacizumab treatment. Further prospective randomized controlled clinical trials are urgently needed.

查看译文

关键词

Angiogenesis,Apatinib,Chemotherapy,Metastatic colorectal cancer,Third-line therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要